- Home
- JSPR vs ICMB Comparison
JSPR vs ICMB Comparison
Compare JSPR & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ICMB
- Stock Information
- Founded
- JSPR 2018
- ICMB 2012
- Country
- JSPR United States
- ICMB United States
- Employees
- JSPR N/A
- ICMB N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ICMB Finance: Consumer Services
- Sector
- JSPR Health Care
- ICMB Finance
- Exchange
- JSPR Nasdaq
- ICMB Nasdaq
- Market Cap
- JSPR 47.6M
- ICMB 40.6M
- IPO Year
- JSPR N/A
- ICMB N/A
- Fundamental
- Price
- JSPR $2.64
- ICMB $2.92
- Analyst Decision
- JSPR Buy
- ICMB
- Analyst Count
- JSPR 12
- ICMB 0
- Target Price
- JSPR $30.78
- ICMB N/A
- AVG Volume (30 Days)
- JSPR 175.5K
- ICMB 25.8K
- Earning Date
- JSPR 11-06-2025
- ICMB 08-12-2025
- Dividend Yield
- JSPR N/A
- ICMB 16.44%
- EPS Growth
- JSPR N/A
- ICMB N/A
- EPS
- JSPR N/A
- ICMB 0.93
- Revenue
- JSPR N/A
- ICMB $20,422,069.00
- Revenue This Year
- JSPR N/A
- ICMB N/A
- Revenue Next Year
- JSPR N/A
- ICMB N/A
- P/E Ratio
- JSPR N/A
- ICMB $3.14
- Revenue Growth
- JSPR N/A
- ICMB N/A
- 52 Week Low
- JSPR $2.27
- ICMB $2.46
- 52 Week High
- JSPR $26.05
- ICMB $3.47
- Technical
- Relative Strength Index (RSI)
- JSPR 34.62
- ICMB 60.24
- Support Level
- JSPR $2.58
- ICMB $2.88
- Resistance Level
- JSPR $2.87
- ICMB $2.97
- Average True Range (ATR)
- JSPR 0.12
- ICMB 0.08
- MACD
- JSPR 0.02
- ICMB 0.01
- Stochastic Oscillator
- JSPR 8.51
- ICMB 61.76
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.